Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders

被引:102
作者
Ketter, TA
Manji, HK
Post, RM
机构
[1] Stanford Univ, Dept Psychiat & Behav Sci, Bipolar Disorders Clin, Stanford, CA 94305 USA
[2] US Dept HHS, NIMH, Bethesda, MD USA
关键词
D O I
10.1097/01.jcp.0000088915.02635.e8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Based on the mood-stabilizing properties of carbamazepine and valproate, new anticonvulsants have been explored for use in bipolar disorders. One such agent lamotrigine, has recently been approved as a maintenance treatment for bipolar I disorder, and has a novel clinical profile in that it may "stabilize mood from below," as it appears to maximally impact depressive symptoms in bipolar disorders. In this paper, we review the mechanisms of action of lamotrigine in an effort to understand the basis of its distinctive clinical use in the management of bipolar disorders as well as its diverse antiseizure effects. We consider lamotrigine mechanisms, emphasizing commonalities and dissociations among actions of lamotrigine, older mood stabilizers, and other anticonvulsants. Although ion channel effects, especially sodium channel blockade, may importantly contribute to antiseizure effects, such actions may be less central to lamotrigine thymoleptic effects. Antiglutamatergic and neuroprotective actions are important candidate mechanisms for lamotrigine psychotropic effects. Lamotrigine has a variable profile in kindling and contingent tolerance experiments and does not appear to have robust gamma-aminobutyric acid or monoaminergic actions. Lamotrigine intracellular signaling effects warrant investigation. Although lamotrigine mechanisms overlap those of other mood-stabilizing anticonvulsants, important dissociations suggest candidate mechanisms, which could contribute to lamotrigine's distinctive psychotropic profile.
引用
收藏
页码:484 / 495
页数:12
相关论文
共 128 条
[71]  
MASON GF, 2000, 39 ANN M AM COLL NEU, P304
[72]   200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial [J].
McCleane, G .
PAIN, 1999, 83 (01) :105-107
[73]  
*MED EC COMP INC, 2003, PHYS DESK REF
[74]  
MELDRUM BS, 1996, EPILIPSIA, V37, P4
[75]   Lithium-induced increase in human brain grey matter [J].
Moore, GJ ;
Bebchuk, JM ;
Wilds, IB ;
Chen, G ;
Menji, HK .
LANCET, 2000, 356 (9237) :1241-1242
[76]   Lithium increases N-acetyl-aspartate in the human brain:: In vivo evidence in support of bcl-2's neurotrophic effects? [J].
Moore, GJ ;
Bebchuk, JM ;
Hasanat, K ;
Chen, G ;
Seraji-Bozorgzad, N ;
Wilds, IB ;
Faulk, MW ;
Koch, S ;
Glitz, DA ;
Jolkovsky, L ;
Manji, HK .
BIOLOGICAL PSYCHIATRY, 2000, 48 (01) :1-8
[77]  
MOTOHASHI N, 1992, PROG NEURO-PSYCHOPH, V16, P571
[78]   GABAB RECEPTORS ARE UP-REGULATED BY CHRONIC TREATMENT WITH LITHIUM OR CARBAMAZEPINE - GABA HYPOTHESIS OF AFFECTIVE-DISORDERS [J].
MOTOHASHI, N ;
IKAWA, K ;
KARIYA, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 166 (01) :95-99
[79]   ANTIEPILEPTIC DRUGS AND MECHANISMS OF EPILEPTOGENESIS - A REVIEW [J].
MUTANI, R ;
CANTELLO, R ;
GIANELLI, M ;
CIVARDI, C .
ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1995, 16 (04) :217-222
[80]   Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors [J].
Nowak, G ;
Legutko, B ;
Skolnick, P ;
Popik, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 342 (2-3) :367-370